Eloxx Pharmaceuticals, Inc. Stock Price Today
Eloxx Pharmaceuticals, Inc. stock price today. Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) is currently trading at $13.45 USD, up 1.89% today. Over the past 52 weeks, shares have ranged between $12.21 and $18.53. This page tracks Eloxx Pharmaceuticals, Inc.'s live share price on the NASDAQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Eloxx Pharmaceuticals, Inc. (ELOX) total market value.
Share Price of Eloxx Pharmaceuticals, Inc. — Daily History & Trading Volume
Share price of Eloxx Pharmaceuticals, Inc. over the past year. The chart below tracks Eloxx Pharmaceuticals, Inc.'s daily closing share price and trading volume on the NASDAQ exchange over the past year, giving a clear view of recent price momentum and liquidity.
Eloxx Pharmaceuticals, Inc. Stock Trading Volume
Eloxx Pharmaceuticals, Inc. stock trading volume shows how many shares changed hands each day on the NASDAQ exchange.
Eloxx Pharmaceuticals, Inc. Income Statement — Revenue, Profit & Earnings by Year
Eloxx Pharmaceuticals, Inc.'s annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2016 |
|---|---|---|---|---|---|
| Total Revenue | $0.00 | $6.36 Million | $0.00 | $0.00 | $75.00K |
| Cost of Revenue | — | — | — | $695.00K | $93.39K |
| Gross Profit | — | $6.36 Million | — | $-695.00K | $-18.39K |
| Research & Development | $3.06 Million | $3.58 Million | $8.60 Million | $23.73 Million | $2.09 Million |
| SG&A | $3.38 Million | $5.25 Million | $8.69 Million | $10.69 Million | — |
| Total Operating Expenses | $6.44 Million | $8.83 Million | $17.29 Million | $33.72 Million | $3.70 Million |
| Operating Income | $-6.44 Million | $-2.47 Million | $-17.29 Million | $-34.42 Million | $-3.71 Million |
| EBITDA | $-4.95 Million | $-1.83 Million | $-15.09 Million | $-33.50 Million | $-3.62 Million |
| EBIT | $-4.95 Million | $-2.00 Million | $-15.90 Million | $-34.19 Million | $-3.71 Million |
| Interest Expense | $1.05 Million | $1.14 Million | $1.15 Million | $1.95 Million | — |
| Income Before Tax | $-6.00 Million | $-3.14 Million | $-17.05 Million | $-36.14 Million | $-8.95 Million |
| Income Tax Expense | — | — | — | $-77.00K | $-680.00K |
| Net Income | $-6.00 Million | $-3.14 Million | $-17.05 Million | $-36.06 Million | $-8.27 Million |
Eloxx Pharmaceuticals, Inc. Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Eloxx Pharmaceuticals, Inc.'s financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | $5.27 Million | $2.98 Million | $1.71 Million | $21.12 Million | $45.14 Million |
| Total Current Assets | $5.27 Million | $2.98 Million | $1.55 Million | $20.13 Million | $43.48 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | — | — | — | — |
| Net Receivables | $0.00 | $2.72 Million | $0.00 | — | — |
| Inventory | — | — | — | — | — |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | — | — | — | — | — |
| Total Liabilities | $17.18 Million | $27.31 Million | $24.31 Million | $31.78 Million | $22.75 Million |
| Total Current Liabilities | $17.18 Million | $27.31 Million | $22.70 Million | $23.09 Million | $9.96 Million |
| Long-term Debt | — | — | $1.61 Million | $8.56 Million | — |
| Net Debt | $-3.79 Million | $6.41 Million | $2.83 Million | $-6.08 Million | $-29.11 Million |
| Total Stockholder Equity | $-11.91 Million | $-24.34 Million | $-22.60 Million | $-10.66 Million | $22.38 Million |
| Retained Earnings | $-300.58 Million | $-294.58 Million | $-291.44 Million | $-274.39 Million | $-238.32 Million |
Eloxx Pharmaceuticals, Inc. Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Eloxx Pharmaceuticals, Inc. generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | $-6.33 Million | $-4.71 Million | $-14.34 Million | $-31.84 Million | $-35.00 Million |
| Capital Expenditures | $6.33 Million | $0.00 | $0.00 | $66.00K | $89.00K |
| Free Cash Flow | $-6.33 Million | $-4.71 Million | $-14.34 Million | $-31.91 Million | $-35.09 Million |
| Investing Cash Flow | $1.00K | $38.00K | $309.00K | $-66.00K | $2.06 Million |
| Financing Cash Flow | $11.00 Million | $3.44 Million | $-4.08 Million | $8.81 Million | $50.79 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | $235.00K | $541.00K | $1.97 Million | $3.02 Million | — |
| Depreciation | $0.00 | $164.00K | $809.00K | $695.00K | $960.00K |
| Change in Cash | $-14.68 Million | $-1.24 Million | $-18.11 Million | $-23.10 Million | $17.84 Million |
Eloxx Pharmaceuticals, Inc. Earnings History — EPS Actual vs. Analyst Estimates
Track Eloxx Pharmaceuticals, Inc.'s quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Nov 10, 2026 | — | — | — |